HUTCHMED will take a data-light but strategy-heavy slate to WCLC and CSCO next week, led by updated analyses from savolitinib’s SACHI and SAVANNAH programs, a Phase IIIb confirmatory study in NSCLC, and first-in-human results for HMPL-653, a CSF-1R inhibitor, in tenosynovial giant cell tumor. Additional investigator-initiated updates span fruquintinib and surufatinib combinations across GI, renal, neuroendocrine, and breast cancers.
The core news is fresh readouts that refine the MET story in EGFR-mutant NSCLC following third-generation EGFR-TKI failure and MET exon 14–driven disease. WCLC will feature biomarker concordance and resistance findings from SAVANNAH, patient-reported outcomes for the osimertinib plus savolitinib combination, efficacy and safety in METex14 NSCLC with and without prior immunotherapy, and SACHI insights on treatment duration post-osimertinib. The Phase IIIb confirmatory study indicates a push to solidify evidence where regulatory bodies expect post-approval validation and where global submissions demand more than single-arm or subgroup signals. At CSCO, HUTCHMED will also debut first-in-human data for HMPL-653 in TGCT, a setting where the bar is set by class safety profiles as much as by response.
Strategically, the emphasis on biomarker concordance and acquired resistance appears as a preemptive move to address known friction points in MET-driven development: heterogeneous definitions (overexpression vs. amplification), variable cutoff thresholds, and assay-to-assay variability across IHC, FISH, and NGS. Locking down a reproducible diagnostic framework is now a table stake for regulators and payers, and central to operational scalability across global sites. The PRO analysis in SAVANNAH signals a broader aim to round out the value story for the osimertinib-savolitinib combination, anticipating HTA scrutiny on tolerability and quality-of-life tradeoffs relative to antibody-based, chemo-based, or other targeted strategies. The confirmatory Phase IIIb suggests that HUTCHMED and AstraZeneca are aligning with post-market commitments in China, while also building a dataset that is extensible to ex-China filings.
For sites and CROs, the near-term impact is operational: higher upfront screening burden to identify MET-amplified or overexpressed cohorts; potential central lab dependencies to harmonize assays; and more intensive ePRO capture and adherence oversight in combination regimens. Sponsors and diagnostics partners should read the SAVANNAH concordance work as a signal that companion diagnostic decisions are being actively de-risked, which will influence protocol eligibility criteria, screen failure rates, and geographic site mix. The HMPL-653 TGCT program, if it demonstrates clean safety and a credible response signal, could pave the way for a streamlined development path in a niche indication where single-arm designs can be persuasive. Still, hepatic monitoring frameworks will be scrutinized given the class history.
The breadth of CSCO investigator-initiated updates around fruquintinib and surufatinib underscores a China-first, combination-heavy exploration model that can drive practice adoption domestically but will need randomized, comparator-controlled evidence to travel globally. Expect sponsors to triage which combinations transition from hypothesis-generating IITs to company-led trials with regulatory intent, particularly in colorectal, biliary, and pancreatic settings, where standards are moving targets.
What to watch next: at WCLC, whether savolitinib data show consistent benefit across MET amplification thresholds and assay modalities; clarity on the Phase IIIb confirmatory design and endpoints; and whether PROs demonstrate a differentiated tolerability profile that can withstand payer comparisons. At CSCO, early HMPL-653 safety and dose selection will set the trajectory toward a potential pivotal TGCT study. Across programs, the gating risks remain assay harmonization, screen failure rates, and the need to convert single-arm and retrospective signals into randomized evidence that regulators and HTAs will accept.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
